If you’re into congressional spectacles, stay tuned later this month.
A group of top biopharma executives—the full roster isn’t known yet—will testify at a Feb. 26 hearing before the Senate Committee on Finance to defend their drug pricing practices. No executives showed up for the previous hearing, but reports indicate industry has changed its stance under pressure: Both chambers of Congress have kicked up their efforts to battle drug pricing of late, and the Trump administration just announced a plan to overhaul the secretive rebate deals between drug companies and pharmacy benefit managers.
Will the hearing lead to meaningful change… Read more »
UNDERWRITERS AND PARTNERS
Categories: Avrobio, Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Celgene, clinical trials, CRISPR, Detroit blog main, Detroit top stories, Drugs, Duchenne Muscular Dystrophy, Eli Lilly, FDA, Gene editing, Gene Therapy, Genentech, GlaxoSmithKline, HIV, Indiana blog main, Indiana top stories, Industry, Johnson & Johnson, Life Sciences, National, National blog main, National top stories, New York blog main, New York top stories, Pain Therapeutics, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Sangamo Therapeutics, Sanofi, Sarepta Therapeutics, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories